Related Experiment Video
Updated: Aug 16, 2026

Experimental Endocarditis Model of Methicillin Resistant Staphylococcus aureus (MRSA) in Rat
Published on: June 4, 2012
[Ciprofloxacin in the treatment of staphylococcal endocarditis]
Abstract:
Ciprofloxacin was used in treatment of 5 patients with infectious endocarditis and bacterial vegetations on the values by the findings of the echocardiography. The hemocultures produced the growth of Staphylococcus epidermidis and S. aureus in 3 and 2 patients respectively. The degree of endocarditis was high in 3 patients and intermediate in 2 patients. The drug was administered intravenously in a dose of 200 mg 2 times a day for 4 weeks. The efficacy of the treatment was estimated by following-up the disease time course: the patients were examined prior to the treatment, every week during the treatment and after the treatment completion. The complex clinico-laboratory investigations showed that ciprofloxacin (Ciprinol, KRKA, Slavonia) is a highly efficient chemotherapeutic drug of the group of fluoroquinolones for the treatment of infectious (staphylococcal) endocarditis due to the sensitive microbes. The intravenous drug is useful in treatment of severe forms of infectious endocarditis. The drug is not toxic and well tolerated by the patients after its intravenous administration.
Insights
Ciprofloxacin effectively treated infectious endocarditis caused by Staphylococcus in five patients. This fluoroquinolone antibiotic demonstrated high efficacy and safety for severe staphylococcal endocarditis cases when administered intravenously.
Area of Science:
- Infectious Diseases
- Pharmacology
- Cardiology
Related Concept Videos
Mitral Stenosis III: Medical Management
Endocarditis I: Introduction
Endocarditis III: Medical Management
Endocarditis IV: Nursing Management
Staphylococcal Skin Infections
Inhibitors of Bacterial DNA Synthesis

